Prescriber Criteria Form

Yutrepia 2026 PA Fax 7034-A v2 010126.docx
Yutrepia (treprostinil inhalation powder)
Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.
Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Yutrepia (treprostinil inhalation powder).

Drug Name:
Yutrepia (treprostinil inhalation powder)

Patient Name:		
Patient ID:		
Patient DOB:	**Patient Phone:**	
Prescriber Name:		
Prescriber Address:		
City:	**State:**	**Zip:**
Prescriber Phone:	**Prescriber Fax:**	
Diagnosis:	**ICD Code(s):**	

Please circle the appropriate answer for each question.			
1	Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1) or pulmonary hypertension (PH) associated with interstitial lung disease (WHO Group 3)? [If no, then no further questions.]	Yes	No
2	Has pulmonary hypertension (PH) been confirmed by right heart catheterization? [If no, then no further questions.]	Yes	No
3	Has the patient previously received the requested drug for pulmonary hypertension (PH)? [If yes, then no further questions.]	Yes	No
4	Does the patient meet all of the following criteria: A) pretreatment mean pulmonary arterial pressure is greater than 20 mmHg, B) pretreatment pulmonary capillary wedge pressure less than or equal to 15 mmHg, C) pretreatment pulmonary vascular resistance greater than or equal to 2 Wood units?	Yes	No

Comments:	_____

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

Prescriber (or Authorized) Signature: _____ Date:_____